JP7278777B2 - 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法 - Google Patents

骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法 Download PDF

Info

Publication number
JP7278777B2
JP7278777B2 JP2018561516A JP2018561516A JP7278777B2 JP 7278777 B2 JP7278777 B2 JP 7278777B2 JP 2018561516 A JP2018561516 A JP 2018561516A JP 2018561516 A JP2018561516 A JP 2018561516A JP 7278777 B2 JP7278777 B2 JP 7278777B2
Authority
JP
Japan
Prior art keywords
cancer
cells
compound
drug
folate receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561516A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519524A5 (enExample
JP2019519524A (ja
Inventor
フィリップ・ステュワート・ロウ
ビンビン・ワン
クリストファー・ポール・リーモン
インジュアン・ジェイ・ル
リロイ・ダブリュー・ホイーラー・ザ・セカンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Endocyte Inc
Original Assignee
Purdue Research Foundation
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte Inc filed Critical Purdue Research Foundation
Publication of JP2019519524A publication Critical patent/JP2019519524A/ja
Publication of JP2019519524A5 publication Critical patent/JP2019519524A5/ja
Application granted granted Critical
Publication of JP7278777B2 publication Critical patent/JP7278777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2018561516A 2016-05-25 2017-05-25 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法 Active JP7278777B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341587P 2016-05-25 2016-05-25
US62/341,587 2016-05-25
PCT/US2017/034537 WO2017205661A1 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells

Publications (3)

Publication Number Publication Date
JP2019519524A JP2019519524A (ja) 2019-07-11
JP2019519524A5 JP2019519524A5 (enExample) 2020-07-02
JP7278777B2 true JP7278777B2 (ja) 2023-05-22

Family

ID=60412652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561516A Active JP7278777B2 (ja) 2016-05-25 2017-05-25 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法

Country Status (8)

Country Link
US (2) US20190216935A1 (enExample)
EP (1) EP3463367A4 (enExample)
JP (1) JP7278777B2 (enExample)
KR (1) KR102489277B1 (enExample)
CN (2) CN114903890A (enExample)
AU (1) AU2017271550B2 (enExample)
IL (1) IL263059B2 (enExample)
WO (1) WO2017205661A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763943A (zh) * 2018-08-07 2023-09-19 普渡研究基金会 使car t细胞恢复活力
CN120381528A (zh) * 2019-07-08 2025-07-29 普渡研究基金会 用于治疗和预防纤维化疾病状态和癌症的化合物和方法
CA3184740A1 (en) * 2020-07-08 2022-01-13 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
AU2023232693A1 (en) 2022-03-08 2024-09-19 Connext Co.,Ltd. Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504784A (ja) 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド 多剤リガンド結合体
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
WO2016085967A1 (en) 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
JP2018509424A (ja) 2015-03-13 2018-04-05 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116299A2 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
WO2011014821A1 (en) * 2009-07-31 2011-02-03 Endocyte, Inc. Folate-targeted diagnostics and treatment
CN109517897A (zh) * 2011-04-28 2019-03-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
US9550992B2 (en) * 2011-12-02 2017-01-24 University Of South Florida Compositions and methods for modulating myeloid derived suppressor cells
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CN113620958A (zh) * 2014-03-19 2021-11-09 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
US20170261507A1 (en) * 2014-08-19 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for Predicting and Monitoring Cancer Patients' Response to Teatment by Measuring Myeloid Derived Suppressor Cells (MDSCs)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009504784A (ja) 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド 多剤リガンド結合体
JP2015536323A (ja) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 非天然アミノ酸を含む薬物送達結合体および使用方法
WO2016085967A1 (en) 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
JP2018509424A (ja) 2015-03-13 2018-04-05 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 疾患を処置するためのコンジュゲート

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACS Med.Chem.Lett.，2012年，Vol.3, No.6，p.501-504
FOLATE RECEPTOR BETA: A NEW SURFACE MOLECULE FOR SELECTIVE TARGETING OF ACTIVATED MACROPHAGES IN INFLAMMATORY DISEASES AND CANCER，PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance，2013年，p.1-147
Migration of Myeloid-derived Suppressor Cells to Tumor and Tumor-Draining Lymph Node in a Murine Model of Breast Cancer，University of Wisconsin Milwaukee UWM Digital Commons，2015年，p.1-208
Mol Cancer Ther，2011年，Vol.10, No.12，p.2426-2436
Pteridines，2015年，Vol.26, No.2，p.41-53

Also Published As

Publication number Publication date
KR102489277B1 (ko) 2023-01-16
IL263059B2 (en) 2025-02-01
RU2018145750A3 (enExample) 2020-07-30
CA3025309A1 (en) 2017-11-30
IL263059B1 (en) 2024-10-01
KR20190021261A (ko) 2019-03-05
AU2017271550A1 (en) 2018-12-06
CN109475558A (zh) 2019-03-15
AU2017271550B2 (en) 2023-11-02
EP3463367A1 (en) 2019-04-10
EP3463367A4 (en) 2020-01-29
US20190216935A1 (en) 2019-07-18
JP2019519524A (ja) 2019-07-11
WO2017205661A1 (en) 2017-11-30
US20210170035A1 (en) 2021-06-10
CN114903890A (zh) 2022-08-16
RU2018145750A (ru) 2020-06-25
IL263059A (en) 2018-12-31
BR112018074119A2 (pt) 2019-03-06
NZ748427A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
JP7278777B2 (ja) 骨髄由来サプレッサー細胞のターゲティングにより癌を処置する方法
AU2015205755C1 (en) Compounds and compositions for immunotherapy
JP6869947B2 (ja) 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用
JP5690589B2 (ja) 親水性スペーサーリンカーを含有する結合体
CN102215844A (zh) 抗叶酸剂的叶酸受体结合轭合物
JP2010521485A (ja) 結合性リガンドが結合したツブリシンの薬剤送達結合体
CA2968837A1 (en) Methods of treating cancer by targeting tumor-associated macrophages
US20200038514A1 (en) Folate conjugate for use in targeting tumor associated macrophages
US11981672B2 (en) Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
RU2776899C2 (ru) Способ лечения рака нацеливанием на супрессорные клетки миелоидного происхождения
CA3025309C (en) Method of treating cancer by targeting myeloid-derived suppressor cells
JP2022539804A (ja) 線維性疾患状態およびがんの治療および予防のための化合物ならびに方法
KR20230128509A (ko) 암 치료에서 조작된 세포 요법의 향상을 위한 방법
BR112018074119B1 (pt) Uso de compostos compreendendo um ligante de ligação de receptor folato ligado a um fármaco via um ligante, e composição farmacêutica
CN110678204A (zh) 用于靶向肿瘤相关巨噬细胞的叶酸缀合物
OA16774A (en) Multiple myeloma treatment.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230322

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230322

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230410

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230418

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230510

R150 Certificate of patent or registration of utility model

Ref document number: 7278777

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150